Lymphohistiocytoid mesothelioma is considered one of the least common forms of malignant pleural mesothelioma (LHM), which is one of the most aggressive forms of cancer, characterized by the uncontrolled growth of mesothelial cells constituting the pleura. Leading the way in offering LHM-specific preclinical therapeutic development is Protheragen. We employ a comprehensive system that balances the development of diagnostics, drug discovery, and therapy optimization. We utilize the latest technologies along with a multi-specialty team of professionals.
Overview of Lymphohistiocytoid Mesothelioma (LHM)
Lymphohistiocytoid mesothelioma (LHM) is an uncommon but highly aggressive form of malignant pleural mesothelioma (MPM). This condition is characterized by widespread growth of atypical large histiocytic cells, which form nodules consisting of significant lymphocytic and plasmacytic cells, leading to diffuse proliferation. This particular histological pattern can easily lead to misdiagnosis alongside malignant lymphoma or sarcomatoid carcinoma. Chest pain, shortness of breath, and pleural effusion are all common symptoms that are a part of the clinical presentation. In terms of histology, LHM is characterized by a distinct composite pattern of spindle cells, histiocytic cells, along with dense lymphoplasmacytic infiltration, which adds difficulty to the diagnosis without ancillary studies such as immunohistochemistry and electron microscopy.
Fig.1 A case of pathological analysis of lymphohistiocytoid mesothelioma. (Elahi M.,
et al., 2024)
Diagnostics Development for Lymphohistiocytoid Mesothelioma (LHM)
Imaging Techniques
High-resolution computed tomography (CT) scans can detect pleural thickening, nodular lesions, and pleural effusions, although these findings are nonspecific. Positron emission tomography (PET) scans can further enhance diagnostic accuracy by identifying areas of increased metabolic activity, which is characteristic of malignant cells.
Molecular and Genetic Analysis
Molecular diagnostics involve the detection of specific genetic mutations and biomarkers associated with LHM. Next-generation sequencing (NGS) can identify mutations in genes such as BAP1, CDKN2A, and NF2, which are frequently altered in mesothelioma. These genetic markers can aid in the diagnosis and guide personalized therapeutic strategies.
Immunohistochemistry and Electron Microscopy
Immunohistochemical staining is essential for confirming the diagnosis of LHM. Key markers include calretinin, cytokeratin, and vimentin, which help distinguish LHM from other neoplasms. Electron microscopy can reveal ultrastructural features such as surface microvilli, further supporting the diagnosis.
Therapeutics Development for Lymphohistiocytoid Mesothelioma (LHM)
- Chemotherapy
For LHM, chemotherapy continues to be a mainstay in the patient's therapeutic regimen. Clinical trials have shown remarkable effectiveness with a combination of cisplatin and pemetrexed, with tumor regression and improved overall survival. Other chemotherapy agents like doxorubicin and vinorelbine do tend to be used, although the specific effectiveness in LHM is not as well-established.
- Targeted Therapy
Targeted approaches concentrate on particular molecular pathways pertinent to the development of LHM. For example, therapies aimed at the BAP1 mutation are under investigation. These therapies may potentially stall tumor progression by interfering with the function of mutated proteins and their downstream signaling pathways.
Table 1. Therapeutics of lymphohistiocytoid mesothelioma.
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy |
Cisplatin |
DNA cross-linking |
A platinum-based chemotherapy drug that forms covalent bonds with DNA, preventing cell division and leading to apoptosis. |
Approved |
| Chemotherapy |
Pemetrexed |
Antimetabolite |
Inhibits folate-dependent enzymes, disrupting DNA synthesis and repair, leading to cell death. |
Approved |
| Immunotherapy |
NA |
Immune checkpoint inhibition |
Monoclonal antibody targeting PD-1, enhancing T-cell activity against cancer cells. |
Preclinical |
| Targeted Therapy |
NA |
Anti-angiogenesis |
Monoclonal antibody targeting VEGF, inhibiting angiogenesis and tumor growth. |
Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen provides a full spectrum of services for the development of diagnostics and therapeutics aimed at LHM. Our offerings encompass state-of-the-art imaging techniques, molecular and genetic analysis, along with in-depth histopathological evaluations. Utilizing the latest advancements in technology, we ensure precise diagnostics and the formulation of effective therapeutic solutions. Our integrated, multidisciplinary approach guarantees that every phase of drug and therapy development is executed with the highest level of precision, from preclinical studies through to clinical trials.
Disease Models
- Asbestos-Induced Mesothelioma Models
- BAP1 Knockout Models
- Transgenic MexTAg Mouse Models
- Carcinogen-Induced Models
- Orthotopic/Xenograft Models
Protheragen offers customized services tailored to the specific needs of each client. Our flexible approach allows us to design and execute studies that align with individual research goals. Whether it is the development of a new diagnostic assay or the evaluation of a novel therapeutic agent, we provide comprehensive support at every stage of the research process. If you are interested in our services, please feel free to contact us.
References
- Kanayama, Masatoshi, et al. "Sarcomatoid malignant pleural mesothelioma: a case of long-term recurrence-free survival following curative intent surgery alone." Surgical Case Reports 10.1 (2024): 134.
- Miyamoto, Yosuke, et al. "Lymphohistiocytoid mesothelioma with a response to cisplatin plus pemetrexed: A case report." Cancer treatment communications 4 (2015): 1-5.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
